Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Autoimmune Disease Diagnostics Market
The Autoimmune Disease Diagnostics Market is projected to grow from USD 27.67 billion in 2025 to USD 51.94 billion by 2035, reflecting a compound annual growth rate (CAGR) of 6.5%. This expansion is driven by rising global prevalence of autoimmune disorders, increasing healthcare expenditure, and advancements in diagnostic technologies. The market encompasses systemic and localized autoimmune diseases, with key test types including ANA, CRP, ESR, Rheumatoid Factor, and routine tests.
North America, Europe, and Asia-Pacific remain dominant regions, while emerging markets present untapped growth potential.
Market size
Growth trajectory through 2035
Autoimmune Disease Diagnostics Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Emerging opportunities added
- Expansion in Emerging Markets Rapidly growing healthcare infrastructure in Asia-Pacific, Latin America, and the Middle East & Africa presents significant opportunities for market penetration. Increasing healthcare expenditure and disease awareness are driving demand for diagnostic solutions.
- Development of Point-of-Care Diagnostics The demand for rapid, portable diagnostic tools is rising, particularly in remote and underserved regions. Point-of-care testing enables timely diagnosis and treatment, improving patient outcomes.
- Integration of AI and Machine Learning Artificial intelligence and machine learning are being integrated into diagnostic workflows to enhance accuracy, reduce turnaround times, and personalize treatment plans. These technologies are particularly impactful in interpreting complex biomarker data.
- Collaborations and Partnerships Strategic alliances between diagnostic developers, pharmaceutical companies, and research institutions are fostering innovation. Collaborations accelerate the development of novel diagnostic tools and expand market reach.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $27.67 Bn
- CAGR
- 6.50%
- Expansion
- 1.9×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High Cost of Diagnostic Tools
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Capacity announcements, M&A activity, product launches, and funding rounds tracked quarterly in the full report data pack.
- Study window
- 2020–2035
- Base year
- 2025 (actuals)
Report scope
What this report answers
The specific decisions and questions covered in the 169-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Autoimmune Disease Diagnostics Market today ($27.67 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
- How do EUROPE compare on market share, growth rate, and regulatory posture?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising Prevalence of Autoimmune Diseases) and top restraints (led by High Cost of Diagnostic Tools), with quantified CAGR impact?
- What regulatory shifts and recent tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising Prevalence of Autoimmune Diseases Conditions such as rheumatoid arthritis, lupus, and multiple sclerosis are becoming more prevalent, driving demand for diagnostic solutions. Approximately 5-8% of the global population is affected by autoimmune diseases, necessitating advanced diagnostic tools for early detection and management.
- Advancements in Diagnostic Technologies Innovations in biomarker detection, imaging modalities, and molecular assays are enhancing diagnostic accuracy and efficiency. The development of serological tests, such as ANA and anti-CCP, has improved early-stage diagnosis and monitoring of autoimmune diseases.
- Aging Population and Increased Healthcare Expenditure The global population aged 65 and older is projected to reach 1.5 billion by 2050, increasing the burden of chronic conditions. Healthcare systems are allocating more resources toward managing autoimmune diseases, particularly in developed regions.
- Growing Awareness and Diagnosis Increased public and clinical awareness of autoimmune diseases is leading to earlier and more accurate diagnoses. Campaigns and educational initiatives are improving recognition of symptoms and reducing diagnostic delays.
- Regulatory Support and Approvals Streamlined approval processes for diagnostic tools are accelerating market entry for innovative technologies. Regulatory bodies are prioritizing expedited reviews for high-impact diagnostic solutions, fostering industry growth.
Restraints
Holding it back
- High Cost of Diagnostic Tools Advanced diagnostic technologies, particularly molecular and imaging-based assays, incur significant costs, limiting accessibility in lower-income regions.
- Regulatory and Reimbursement Challenges Stringent regulatory requirements and reimbursement policies can delay market entry for new diagnostic tools, particularly in highly regulated markets like the U.S. and Europe.
- Limited Awareness in Emerging Markets In regions such as Latin America and the Middle East & Africa, limited awareness of autoimmune diseases and diagnostic options restricts market growth.
- Supply Chain Disruptions Component shortages and logistical challenges, particularly post-2025, have impacted the production and distribution of diagnostic kits and equipment.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising Prevalence of Autoimmune Diseases | +2.9% | Global | 2025–2035 |
| Advancements in Diagnostic Technologies | +1.8% | Global | 2025–2035 |
| Aging Population and Increased Healthcare Expenditure | +1.4% | Global | 2025–2035 |
| Growing Awareness and Diagnosis | +1.0% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High Cost of Diagnostic Tools | −1.2% | Global | 2025–2029 |
| Regulatory and Reimbursement Challenges | −0.8% | Global | 2025–2029 |
| Limited Awareness in Emerging Markets | −0.6% | Global | 2025–2029 |
Systemic Autoimm 67% Localized Autoim 33% The Autoimmune Disease Diagnostics Market is segmented by disease type and test type, reflecting the diverse diagnostic needs across conditions and applications.
Revenue share by type · 2025 base year
% OF $27.67 BN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $27.67 Bn Autoimmune Disease Diagnostics Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $27.67 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~41.7% in 2025. Driven by manufacturing scale and end-market density.
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The Autoimmune Disease Diagnostics Market is highly competitive, with a mix of global pharmaceutical giants, specialized diagnostic developers, and emerging players. The competitive landscape is shaped by innovation, strategic partnerships, and mergers and acquisitions.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the market size for the Autoimmune Disease Diagnostics Market?
The global autoimmune disease diagnostics market size is projected to grow from USD 5.23 billion in 2023 to USD 8.29 billion by 2030, exhibiting a CAGR of 6.8 % during the forecast period.
-
• Which region is dominating in the Autoimmune Disease Diagnostics Market?
North America accounted for the largest market in the autoimmune disease diagnostics market.
-
• Who are the major key players in the Autoimmune Disease Diagnostics Market?
Abbott Laboratories, Adaptive Biotechnologies, Beckman Coulter, Becton, Dickinson and Company (BD), BioMerieux, Bio-Rad Laboratories, Danaher Corporation, DiaSorin S.p.A., Fujirebio, Genentech, Grifols.
-
• What are the key trends in the Autoimmune Disease Diagnostics Market?
The development and adoption of point-of-care testing (POCT) for autoimmune diseases are expanding rapidly. POCT devices enable rapid and decentralized testing, allowing for timely diagnosis and treatment initiation in various clinical settings, including primary care offices, emergency departments, and remote healthcare facilities. The expansion of POCT capabilities improves access to autoimmune disease diagnostics, particularly in underserved regions and resource-limited settings.
The Autoimmune Disease Diagnostics Market is projected to reach $51.94 Bn by 2035, up from $27.67 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.